drugset / Trial / NCT02319200

Primary Prevention Hepatocellular Carcinoma by Metformin

NCT02319200 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance. This study is an ancillary of the observational study from the CIRVIR cohort in which more than 1200 patients with compensated HCV cirrhosis are currently included. participating centers : 26

Timeline

Start
2015-06
Primary completion
2016-04
Completion
2016-04

Outcome

Outcome not reported

Stopped: “Decision of investigator”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2000 mg —